HARNESSING THE IMMUNOSUPPRESSIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS (MDSC) TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND GRAFT-VERSUS-HOST DISEASE (GVHD)
Emerging evidence suggests that MDSCs have great potential as an immune intervention modality in both transplantation and autoimmune disease settings. Mount Sinai investigators demonstrated their utility in both GVHD and Type 1 Diabetes. Coupled with a suite of other pending patent applications including a protocol for expansion and differentiation of MDSCs and MDSCs loaded with nanoparticles, this technology is positioned for partnering with a commercial group capable of developing MDSCs as a platform for therapy.
Current Development Status
Capability to load MDSC’s with autoantigens for autoimmune diseases including T1D
Adoptive transfer of MDSC